Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM62E7C)

Drug Name

CPL-7075 Drug Info

Synonyms

Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo

Indication

Disease Entry	ICD 11	Status	REF
Diffuse systemic sclerosis	4A42.1	Phase 3	[1]
Cystic fibrosis	CA25	Phase 2	[2]
Rheumatoid arthritis	FA20	Phase 2	[3]
Systemic lupus erythematosus	4A40.0	Phase 2	[3]
Systemic sclerosis	4A42	Phase 2	[3]

Cross-matching ID

PubChem CID: 3083542
CAS Number: CAS 137945-48-3
TTD Drug ID: DM62E7C

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tumor necrosis factor (TNF)	DTT	TNF	5.692	3.07	4.413	1.202

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diffuse systemic sclerosis

ICD Disease Classification

4A42.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tumor necrosis factor (TNF)	DTT	TNF	1.66E-01	-0.14	-0.65

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03398837) Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (RESOLVE-1). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.